# Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

> clinical trial · VERIFIED · 2026-08-06

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Recurrent Plasmablastic Lymphoma

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07332507

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.